secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001326110-24-000115
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio reports 71% complete response rate in 100-patient ANKTIVA trial; durable responses up to 54 months
--------------------------------------------------------------------------------

- 100 patients with BCG-unresponsive NMIBC CIS enrolled; 71% achieved complete response (CR) rate.
- Durable response duration ranged up to 54 months in responders, supporting cystectomy avoidance.
- Updated data to be submitted to EMA in Marketing Authorization Application in Q4 2024.
- CR rate consistent with 71% reported for 82 patients in NEJM Evidence (Chamie 2022).
- Study continues to monitor durability of responses and overall survival outcomes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611024000115/0001326110-24-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611024000115/ibrx-20241119.htm
  HTML page:      https://secwatch.observer/filing/0001326110-24-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer